XOMA Corp. Stock
Price
Target price
€27.80
€27.80
-0.710%
-0.2
-0.710%
€101.31
17.11.25 / Tradegate
WKN: A2ATUH / Symbol: XOMA / Name: XOMA / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
XOMA Corp. Stock
The price for the XOMA Corp. stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.710%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on XOMA Corp..
With a target price of 101 € there is potential for a 263.31% increase which would mean more than doubling the current price of 27.8 € for XOMA Corp..
So far the community has only identified positive things for XOMA Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of XOMA Corp. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of XOMA Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XOMA Corp. | -0.710% | -4.795% | -6.711% | -2.113% | 13.008% | 57.955% | 3.731% |
| Ardelyx Inc. | -1.900% | -5.514% | 15.994% | 6.969% | 0.785% | 148.955% | 2.248% |
| Krystal Biotech | -0.370% | 0.827% | 8.405% | 6.478% | 16.097% | 135.600% | - |
| Evolus Inc | 1.740% | -4.167% | 7.477% | -49.115% | -45.238% | -20.690% | 98.139% |
Comments
XOMA Royalty (NASDAQ:XOMA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Co. (NASDAQ: XOMA) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Co. (NASDAQ: XOMA) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for XOMA provided by MarketBeat
News
XOMA Revenue Jumps 39% in Fiscal Q2
XOMA (NASDAQ:XOMA), a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company’s revenue (GAAP) reached $13.1 million for Q2
